Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Over the last 12 months, insiders at Merus N.V. have bought $0 and sold $4.88M worth of Merus N.V. stock.
On average, over the past 5 years, insiders at Merus N.V. have bought $42.73M and sold $17.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,706 shares for transaction amount of $211,431 was made by Lundberg Sven Ante (President, CEO & PFO) on 2022‑11‑03.
2024-06-17 | Sale | Silverman Peter B. | COO & GC | 62,000 0.0926% | $56.52 | $3.5M | -1.67% | |
2024-06-12 | Sale | Shuman Harry | VP Controller, PAO | 7,300 0.0112% | $57.84 | $422,232 | -0.88% | |
2024-06-10 | Sale | Shuman Harry | VP Controller, PAO | 1,000 0.0015% | $53.22 | $53,224 | +6.14% | |
2024-06-04 | Sale | Shuman Harry | VP Controller, PAO | 6,000 0.0095% | $52.89 | $317,354 | +9.82% | |
2023-12-19 | Sale | Shuman Harry | VP Controller, PAO | 115 0.0002% | $26.68 | $3,068 | +67.07% | |
2023-12-15 | Sale | Silverman Peter B. | COO & GC | 22,386 0.0386% | $25.00 | $559,650 | +77.95% | |
2023-12-08 | Sale | Shuman Harry | VP Controller, PAO | 250 0.0004% | $24.44 | $6,110 | +86.79% | |
2023-12-01 | Sale | Shuman Harry | VP Controller, PAO | 575 0.001% | $24.58 | $14,134 | +76.41% | |
2023-06-01 | Sale | Shuman Harry | VP Controller, PAO | 575 0.0012% | $21.48 | $12,351 | +16.96% | |
2022-12-13 | Sale | Shuman Harry | VP Controller, PAO | 168 0.0004% | $13.85 | $2,327 | +56.10% | |
2022-12-01 | Sale | Shuman Harry | VP Controller, PAO | 575 0.0015% | $15.35 | $8,826 | +38.99% | |
2022-11-03 | Lundberg Sven Ante | President, CEO & PFO | 14,706 0.0358% | $14.38 | $211,431 | +33.54% | ||
2022-08-25 | Sale | Shuman Harry | VP Controller, PAO | 165 0.0004% | $24.33 | $4,014 | -17.55% | |
2022-08-22 | Lundberg Sven Ante | President, CEO & PFO | 5,826 0.0127% | $22.92 | $133,558 | -12.40% | ||
2022-08-19 | Lundberg Sven Ante | President, CEO & PFO | 704 0.0015% | $22.99 | $16,187 | -13.55% | ||
2022-07-12 | Lundberg Sven Ante | President, CEO & PFO | 4,340 0.0092% | $22.97 | $99,685 | -14.69% | ||
2022-06-01 | Sale | Shuman Harry | VP Controller, PAO | 575 0.0013% | $18.31 | $10,528 | +5.86% | |
2022-03-10 | Sale | Silverman Peter B. | EVP, GC and Head of Utrecht | 60,000 0.133% | $26.95 | $1.62M | -27.93% | |
2021-10-08 | Sale | BVF PARTNERS L P/IL | 10 percent owner | 147,267 0.3769% | $27.79 | $4.09M | -9.47% | |
2021-10-07 | Sale | BVF PARTNERS L P/IL | 10 percent owner | 985,447 2.5542% | $27.53 | $27.13M | -7.26% |
Shuman Harry | VP Controller, PAO | 7002 0.0121% | $56.99 | 0 | 11 | |
Silverman Peter B. | COO & GC | 0 0% | $56.99 | 0 | 3 | |
BVF PARTNERS L P/IL | 10 percent owner | 232747 0.4031% | $56.99 | 12 | 3 | +25.67% |
Throsby Mark | EVP & Chief Scientific Officer | 45515 0.0788% | $56.99 | 0 | 6 | |
Lundberg Sven Ante | President, CEO & PFO | 40576 0.0703% | $56.99 | 4 | 0 | <0.0001% |
de Kruif John | SVP & Chief Technology Officer | 15282 0.0265% | $56.99 | 0 | 2 | |
Bakker Lex | SVP, Chief Development Officer | 8668 0.015% | $56.99 | 0 | 1 |
Commodore Capital, LP | $196.33M | 7.43 | 4.36M | -8.16% | -$17.44M | 13.84 | |
RTW Investments, LP | $185.05M | 7 | 4.11M | +73.13% | +$78.16M | 2.74 | |
Deerfield Management | $119.3M | 4.51 | 2.65M | -12.27% | -$16.68M | 2.31 | |
Federated Hermes | $101.26M | 3.83 | 2.25M | -38.17% | -$62.52M | 0.23 | |
Samlyn Capital, LLC | $93.51M | 3.54 | 2.08M | -39.15% | -$60.15M | 1.64 | |
Boxer Capital, LLC | $85.56M | 3.24 | 1.9M | 0% | +$0 | 4.28 | |
Franklin Templeton Investments | $84.35M | 3.19 | 1.87M | -0.52% | -$443,230.20 | 0.03 | |
Vr Adviser Llc | $80.61M | 3.05 | 1.79M | -16.66% | -$16.12M | 3.92 | |
Fidelity Investments | $74.86M | 2.83 | 1.66M | +127.61% | +$41.97M | 0.01 | |
Lynx1 Capital Management Lp | $67.95M | 2.57 | 1.51M | +32.93% | +$16.83M | 3.58 | |
BlackRock | $66.1M | 2.5 | 1.47M | +2.66% | +$1.71M | <0.01 | |
Wellington Management Company | $56.23M | 2.13 | 1.25M | -37.86% | -$34.26M | 0.01 | |
Driehaus Capital Management LLC | $55.23M | 2.09 | 1.23M | -6.45% | -$3.81M | 0.55 | |
T. Rowe Price | $53.38M | 2.02 | 1.19M | New | +$53.38M | 0.01 | |
Bvf Inc Il | $52.79M | 2 | 1.17M | -57.41% | -$71.16M | 0.39 | |
Medicxi Growth I Lp | $52.64M | 1.99 | 1.17M | -26.94% | -$19.41M | 13.8 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $51.63M | 1.95 | 1.15M | +31.48% | +$12.36M | 1.32 | |
Morgan Stanley | $44.03M | 1.67 | 977,855 | +134.76% | +$25.28M | <0.01 | |
Holocene Advisors, LP | $42.31M | 1.6 | 939,576 | New | +$42.31M | 0.16 | |
Avoro Capital Advisors Llc | $40.03M | 1.52 | 888,888 | 0% | +$0 | 0.48 | |
Frazier Life Sciences Management L P | $33.61M | 1.27 | 746,479 | 0% | +$0 | 1.73 | |
T Rowe Price Investment Management Inc | $32.83M | 1.24 | 729,015 | New | +$32.83M | 0.02 | |
Two Sigma Advisers LP | $32.35M | 1.22 | 718,500 | +66.51% | +$12.92M | 0.06 | |
Fairmount Funds Management LLC | $32.3M | 1.22 | 717,254 | 0% | +$0 | 3.52 | |
Cormorant Asset Management Lp | $32.2M | 1.22 | 715,000 | New | +$32.2M | 1.53 | |
Two Sigma | $32.07M | 1.21 | 712,109 | +126.03% | +$17.88M | 0.06 | |
Woodline Partners LP | $30.21M | 1.14 | 670,799 | +175.79% | +$19.25M | 0.29 | |
Silverarc Capital Management Llc | $25.5M | 0.97 | 566,287 | -12.28% | -$3.57M | 7.51 | |
5Am Venture Management Llc | $24.71M | 0.94 | 548,825 | +5.23% | +$1.23M | 1.66 | |
Janus Henderson | $24.43M | 0.93 | 542,580 | +2.17% | +$519,350.71 | 0.01 | |
Artal Group S A | $20.49M | 0.78 | 455,081 | New | +$20.49M | 0.11 | |
DAFNA Capital Management, LLC | $17.07M | 0.65 | 378,995 | -16.68% | -$3.42M | 3.97 | |
Saturn V Capital Management Llc | $16.96M | 0.64 | 376,629 | -3.26% | -$572,061.12 | 6.8 | |
Citadel Advisors LLC | $15.86M | 0.6 | 352,208 | +25.68% | +$3.24M | 0.01 | |
Adage Capital Partners Gp L L C | $14.63M | 0.55 | 325,000 | -1.51% | -$225,150.00 | 0.03 | |
Tri Locum Partners Lp | $12.89M | 0.49 | 286,322 | New | +$12.89M | 4.55 | |
D. E. Shaw & Co. | $12.32M | 0.47 | 273,526 | +363.34% | +$9.66M | 0.02 | |
Ally Bridge Group | $11.52M | 0.44 | 255,928 | -6.91% | -$855,344.86 | 6.48 | |
Spyglass Capital Management LLC | $11.49M | 0.44 | 255,109 | -28.16% | -$4.5M | 8.61 | |
State Street | $11.02M | 0.42 | 244,676 | +3.81% | +$404,729.63 | <0.0001 | |
Great Point Partners | $10.05M | 0.38 | 223,288 | +1,016.44% | +$9.15M | 1.68 | |
Soleus Capital Management, L.P. | $8.81M | 0.33 | 195,577 | -35.36% | -$4.82M | 0.08 | |
Integral Health Asset Management Llc | $7.43M | 0.28 | 165,000 | New | +$7.43M | 0.74 | |
The Vanguard Group | $7.03M | 0.27 | 156,149 | +2.76% | +$188,765.77 | <0.0001 | |
Td Asset Management Inc | $6.81M | 0.26 | 151,174 | New | +$6.81M | 0.01 | |
Millennium Management LLC | $6.77M | 0.26 | 150,270 | -78.33% | -$24.45M | 0.01 | |
Sphera Fund | $6.72M | 0.25 | 149,333 | -35.17% | -$3.65M | 1.11 | |
Invesco | $5.78M | 0.22 | 128,249 | +170.77% | +$3.64M | <0.01 | |
ExodusPoint Capital Management, LP | $5.61M | 0.21 | 124,628 | +218.85% | +$3.85M | 0.07 | |
Walleye Capital | $5.51M | 0.21 | 122,254 | New | +$5.51M | 0.02 |